Discovery and Development of First-in-Class Cereblon-Recruiting RIPK1 Degraders

This study reports the discovery and development of LD5095, a first-in-class cereblon-recruiting degrader that potently and durably eliminates RIPK1 to sensitize tumor cells to apoptosis, demonstrating favorable pharmacokinetics and promising potential as both a chemical probe and a cancer therapeutic.

The Gist

The Big Picture: A "Wanted" Poster for a Bad Protein

Imagine your body is a bustling city. Inside the cells of this city, there are thousands of workers (proteins) doing specific jobs. One of these workers is called RIPK1.

In a healthy city, RIPK1 is a helpful security guard. But in certain diseases, like cancer, RIPK1 gets a promotion to "Bad Boss." It starts helping tumors hide from the immune system (the city's police force) and resist treatment. It's like a corrupt official bribing the police to ignore the criminals.

Scientists have been trying to stop this Bad Boss. Some tried to just "fire" him by using inhibitors (like putting a gag over his mouth), but he kept finding ways to keep working. This team of scientists decided to try a different approach: Don't just silence him; fire him and throw him in the trash.

The Solution: The "Molecular Trash Can" (PROTACs)

To get rid of RIPK1 permanently, the scientists invented a special tool called a PROTAC (which sounds like "protagonist," but really stands for Proteolysis Targeting Chimera).

Think of a PROTAC as a two-sided magnet or a molecular glue stick:

1. Side A (The Hook): Grabs onto the Bad Boss (RIPK1).
2. Side B (The Hook): Grabs onto the city's Trash Can (an E3 ligase enzyme called Cereblon, or CRBN).
3. The Bridge: A flexible chain connecting the two hooks.

When the PROTAC attaches to both, it forces the Trash Can to grab the Bad Boss, tag him with a "Take Me Out" sticker (ubiquitin), and dump him into the cell's garbage disposal (the proteasome). The cell then recycles the trash, and the Bad Boss is gone forever.

The Journey: From "Clunky" to "Perfect"

The scientists didn't get it right on the first try. They had to play a game of "Molecular Tetris" to build the perfect trash-collecting tool.

1. The Linker Problem (The Rope Length)
Imagine trying to tie a dog (the Bad Boss) to a trash can using a rope.

• If the rope is too short, they can't reach each other.
• If the rope is too long, they get tangled and can't pull the trash can close enough.
• The Fix: The scientists tested ropes of different lengths (3 to 11 carbon atoms). They found that a specific length (11 atoms) was just right to let the Bad Boss and the Trash Can hug tightly.

2. The Trash Can Problem (The CRBN Ligand)
They needed the best "Trash Can" to use. They tried different types of "glue" to stick to the Trash Can.

• Some glues were weak.
• One specific glue (called an "N-linked degron") turned out to be super-strong. It made the Trash Can grab the Bad Boss much more efficiently.

3. The Stability Problem (The Rigid Bridge)
Early versions of their tool were like a floppy noodle. They worked okay, but the body's liver (the city's maintenance crew) broke them down too fast.

• The Fix: They replaced the floppy noodle with a rigid, steel-reinforced bridge. This made the tool much harder for the liver to break down, allowing it to stay in the body longer.

The Star Player: LD5095

After all this testing, they created their champion: LD5095.

• Super Strong: It is incredibly good at finding and destroying RIPK1. It works at very low doses (nanomolar range), meaning you only need a tiny amount to do the job.
• Long-Lasting: Unlike previous tools that disappeared quickly, LD5095 stays in the system for a long time. In mice, a single dose kept destroying the Bad Boss for 6 full days.
• Selective: It's a "sniper," not a "shotgun." It only targets RIPK1 and ignores all the other good workers in the cell. This is crucial because it means fewer side effects.

Why This Matters for Cancer Treatment

The paper shows that when you use LD5095 to remove RIPK1 from cancer cells:

1. The Walls Come Down: The cancer cells stop hiding.
2. The Police Arrive: When combined with a standard immunotherapy drug (like anti-PD1), the body's immune system suddenly sees the cancer clearly.
3. The Result: The cancer cells die (apoptosis).

Think of it like this: The cancer was wearing a "Do Not Disturb" sign. LD5095 rips that sign off. Then, the immune system (the police) comes in and arrests the criminals.

The Catch (And the Future)

There is one small hiccup. This tool works perfectly in human cells, but it doesn't work in mouse cells.

• Why? The "Trash Can" in mice is slightly shaped differently than in humans. The glue (LD5095) fits the human Trash Can perfectly but slips off the mouse one.
• What's Next? Since we can't test this in normal mice, the scientists plan to use "humanized mice" (mice with human immune systems) to prove it works in a living body before moving to human clinical trials.

The Bottom Line

This paper describes the creation of LD5095, a first-of-its-kind "molecular trash collector" designed specifically to hunt down and destroy the cancer-helping protein RIPK1. It is highly effective, stays in the body for a long time, and could be a game-changer for making immunotherapy work better against tough cancers. It's a promising new key for a lock that has been very hard to open.

Technical Summary

1. Problem Statement

Receptor-interacting protein kinase 1 (RIPK1) is a critical regulator of programmed cell death (apoptosis and necroptosis) and a driver of tumor resistance to immune checkpoint inhibitors (ICBs). While pharmacological degradation of RIPK1 offers a promising therapeutic strategy to sensitize tumors to immunotherapy, existing RIPK1 degraders (primarily based on VHL-recruiting PROTACs) suffer from poor pharmacokinetic (PK) profiles, including high in vivo clearance and low plasma concentrations. Furthermore, there is a lack of fully characterized RIPK1 degraders utilizing the Cereblon (CRBN) E3 ligase recruitment strategy, which is known for better oral bioavailability and favorable PK properties in clinical settings.

2. Methodology

The study employed a systematic medicinal chemistry approach to design, synthesize, and optimize a new class of CRBN-recruiting PROTACs targeting RIPK1.

• Design Strategy: The PROTACs consisted of three components:
  1. Warhead: A Type II RIPK1 inhibitor (T2I) derived from a known scaffold.
  2. E3 Ligase Ligand: Various CRBN binders (e.g., pomalidomide, thalidomide derivatives, and non-thalidomide chemotypes).
  3. Linker: Systematic optimization of linker length (aliphatic chains), rigidity (cyclic structures, spirocycles), and attachment points ("exit vectors").
• Synthesis: Multiple synthetic routes were established (Schemes 1–4) to generate libraries of compounds. Key steps included nucleophilic aromatic substitution, amide coupling, Sonogashira coupling, and Suzuki coupling to assemble the ternary structures.
• In Vitro Screening:
  • Degradation Potency: Measured using nLuc-RIPK1 expressing Jurkat cells and Western blot analysis of endogenous RIPK1 in WT Jurkat, MOLM14, and U937 cell lines.
  • Metabolic Stability: Assessed in mouse liver S9 fractions to determine half-life ($T_{1/2}$).
  • Mechanism Validation: Confirmed PROTAC mode of action using negative controls (warhead alone, ligand alone, methylated glutarimide control) and inhibitors of the ubiquitin-proteasome system (UPS) (e.g., Carfilzomib, MLN4924, TAK-243).
  • Selectivity: Global proteomics (mass spectrometry) on MOLM14 cells to assess off-target degradation.
• In Vivo Evaluation:
  • Pharmacokinetics (PK): Intravenous (IV) and oral administration in mice to measure clearance, half-life, and bioavailability.
  • Pharmacodynamics (PD): Xenograft models (Jurkat cells in nude mice) to assess sustained target degradation over time (up to 144 hours).
  • Functional Assays: Evaluation of sensitization to TNF$\alpha$-induced apoptosis.

3. Key Contributions

• First-in-Class CRBN-Recruiting RIPK1 Degrader: The study reports the first fully characterized RIPK1 PROTAC utilizing CRBN recruitment, addressing the PK limitations of previous VHL-based degraders.
• Lead Compound Identification (LD5095): Through iterative optimization of the CRBN ligand, linker rigidity, and exit vector, the authors identified LD5095 (Compound 18a) as a superior lead candidate.
• Structure-Activity Relationship (SAR) Insights:
  • Linker Rigidity: Replacing flexible aliphatic linkers with rigid cyclic linkers (e.g., spiro[3.3]heptane) significantly improved metabolic stability without compromising potency.
  • CRBN Ligand: An N-linked degron (Compound 5b) showed superior activity compared to standard thalidomide moieties.
  • Exit Vector: Incorporating a cyclic exit vector further enhanced stability and potency.
• Resolution of the "Hook Effect": The optimization process successfully mitigated the hook effect observed in earlier iterations (e.g., Compound 3d), ensuring high degradation efficacy at therapeutic concentrations.

4. Key Results

• Potency and Selectivity:
  • LD5095 demonstrated exceptional potency with $DC_{50}$ values of 1.4 nM (Jurkat), 1.2 nM (MOLM14), and 2.3 nM (U937).
  • It achieved maximum degradation ($D_{max}$) of >90% in Jurkat cells.
  • Proteomic profiling confirmed high selectivity, with no significant degradation of off-target kinases despite the use of a "dirty" warhead, attributed to the requirement for a productive ternary complex.
• Metabolic Stability and PK:
  • LD5095 exhibited remarkable metabolic stability in mouse liver S9 fractions ($T_{1/2} > 120$ min), a significant improvement over earlier flexible-linker analogs.
  • IV PK: $T_{1/2} = 21.2$ hours, $Cl_{plasma} = 4.9$ mL/min/kg, $AUC_{0-last} = 2903$ h·ng/mL.
  • Oral Bioavailability: Following oral dosing (20 mg/kg), LD5095 showed a $C_{max}$ of 304 ng/mL and a terminal half-life of 7.3 hours, confirming drug-like properties suitable for oral administration.
• Sustained In Vivo Degradation:
  • In Jurkat xenografts, a single IV dose (10 mg/kg) of LD5095 resulted in >85% RIPK1 degradation at 144 hours (6 days) post-administration. This contrasts sharply with previous VHL-based degraders which showed rapid target recovery.
• Functional Activity:
  • LD5095 alone showed no intrinsic cytotoxicity in unstimulated cells.
  • However, it significantly sensitized Jurkat cells to TNF$\alpha$-induced apoptosis, evidenced by increased cleavage of Caspase-3/7 and PARP, and reduced cell viability. This effect was reversed by the pan-caspase inhibitor Z-VAD-FMK.
• Species Specificity: Consistent with other CRBN-based degraders, LD5095 showed negligible activity in murine B16F10 cells, highlighting a species-specific limitation for murine syngeneic models but validating its utility in humanized models.

5. Significance

• Therapeutic Potential: LD5095 represents a major advancement in RIPK1-targeted therapy. Its favorable PK profile (long half-life, oral bioavailability) and sustained in vivo degradation make it a viable candidate for clinical development, particularly for combination therapies with immune checkpoint inhibitors (ICIs) to overcome tumor resistance.
• Chemical Probe: Due to its high potency, selectivity, and sustained degradation, LD5095 serves as an invaluable chemical probe for studying the biological roles of RIPK1 in adult development, infectious diseases, and cancer, filling a gap left by the lethality of RIPK1 knockout mice.
• Proof of Concept: The study validates that switching from VHL to CRBN recruitment, combined with rigid linker design, can overcome the pharmacokinetic liabilities of large PROTAC molecules, setting a precedent for future degrader development.